Prosecution Insights
Last updated: April 19, 2026
Application No. 18/033,974

IMMUNOISOLATION DEVICE

Non-Final OA §102§103§112
Filed
Apr 26, 2023
Examiner
BEISNER, WILLIAM H
Art Unit
1799
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Kuraray Co. Ltd.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
3y 8m
To Grant
91%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
576 granted / 940 resolved
-3.7% vs TC avg
Strong +30% interview lift
Without
With
+30.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
36 currently pending
Career history
976
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
40.4%
+0.4% vs TC avg
§102
20.9%
-19.1% vs TC avg
§112
24.7%
-15.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 940 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Priority Receipt is acknowledged of certified copies of papers (JAPAN 2020-180919 10/28/2020) required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements dated 4/26/2023, 2/20/2024 and 10/2/2024 have been considered and made of record. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 14 and 18-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claim 14, “the hydrogel” lacks antecedent basis. Note: claim 14 depends from claim 1 which is devoid of language providing antecedent basis for “the hydrogel”. Clarification and/or correction is requested. In claims 18-20, “the thickness of multiple layers” lacks clear antecedent basis. Note: Claims 18-20 depend from claim 1 which is devoid of language providing antecedent basis for “the thickness of multiple layers”. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4, 9, 12-14, 17 and 18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mochizuki et al. (US 2019/0262509). With respect to claim 1, the reference of Mochizuki et al. discloses: An immunoisolation device comprising an embedding chamber (chamber) (¶[0131]-[0140] for a material to be transplanted, the embedding chamber being covered with an immunoisolation membrane (membrane for immunoisolation)(¶[0131]). With respect to claims 2, 3, 9 and 12, the reference of Mochizuki et al. discloses that the immunoisolation membrane can comprise a porous membrane layer (porous membrane) and a hydrogel layer (hydrogel membrane)(¶[0049] and [0119]-[0120]). With respect to claim 12, the structure resulting from the product by product language of claim 12 would be structurally the same as the layered membrane disclosed by the reference of Mochizuki et al. With respect to claim 4, the immunoisolation membrane suppresses entry of immunoresponsive cells and immune system humoral factors into the embedding chamber (¶[0046]-[0048]). With respect to claim 13, the immunoisolation membrane of the reference of Mochizuki et al. comprises a porous membrane of an ethylene-vinyl alcohol copolymer (¶[0088]). With respect to claim 14, the hydrogel of the reference of Mochizuki et al. can be a polyvinyl alcohol-based polymer (¶[0120]). With respect to claims 17 and 18, the reference of Mochizuki et al. discloses that the membrane can have a thickness meeting the limitations of claim 17 (¶[0051] and [0066]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 5-7 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Mochizuki et al. (US 2019/0262509). The reference of Mochizuki et al. has been discussed above with respect to claim 1. Claims 5-7 differ by reciting properties of the membrane that are not specifically disclosed in the disclosure of the reference of Mochizuki et al. However, the reference of Mochizuki et al. discloses that the selective permselectivity of the membrane can be adjusted according to the application (¶[0048]). In view of this disclosure and in the absence of a showing of unexpected results, it would have been obvious to one of ordinary skill in the art to determine the optimal permselectivity and strength of the membrane based on design considerations such as the cells to be used, the environment to be use, the size and structure of the chamber, etc. while maintaining the efficiency of the device. With respect to claim 15, in the absence of a showing of unexpected results, it would have been well within the purview of one having ordinary skill in the art to determine which side of the membrane would be optimal for contact with the cells and/or external environment through routine experimentation. Claims 8, 10, 11, 16, 19 and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Mochizuki et al. (US 2019/0262509) in view of Bou Aoun et al. (US 2018/0311282). The reference of Mochizuki et al. has been discussed above with respect to claims 1-4, 9, 12-14, 17 and 18. Claims 8, 10, 11, 16, 19 and 20 differ by reciting that the immunoisolation membrane includes a fiber structure layer. The reference of Bou Aoun et al. discloses that it is known in the art to strengthen an immunoisolation membrane while minimizing thickness that is detrimental to diffusion by including a fiber structure layer (non-woven polymer)(¶[0012]-[0017] and [0023]-[0033]). In view of this teaching and in the absence of a showing of unexpected results, it would have been obvious to one of ordinary skill in the art to include a fiber structure layer with the immunoisolation membrane of the reference of Mochizuki et al. for the known and expected result of increasing the mechanical structure of the membrane as evidenced by the reference of Bou Aoun et al. With respect to claims 10, 11 and 16, in the absence of a showing of unexpected results, it would have been obvious to determine the optimal manner in which to form the multiple layered membrane while providing the final structure required for the intended use of the device. With respect to claims 19 and 20, both the references of Mochizuki et al. and Bou Aoun et al. discloses that the membrane can have a thickness meeting the limitations of claim 17 (¶[0051] and [0066] of Mochizuki et al. and ¶[0101]-[0111] of Bou Aoun et al.). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The references of Kawagoe et al. (US 2019/0015547) and Fournier et al. (WO 97/17129) are cited as prior art which pertain to immunoisolation membrane devices. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WILLIAM H BEISNER whose telephone number is (571)272-1269. The examiner can normally be reached on Mon-Fri from 8am to 5pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MICHAEL A MARCHESCHI, can be reached at telephone number (571)272-1374. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /William H. Beisner/ Primary Examiner Art Unit 1799 WHB
Read full office action

Prosecution Timeline

Apr 26, 2023
Application Filed
Jan 09, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584901
ELECTRONIC SINGLE USE CHEMICAL DIAGNOSTICS DEVICE
2y 5m to grant Granted Mar 24, 2026
Patent 12576434
LIVESTOCK CARCASS TREATMENT SYSTEM USING ULTRA-HIGH TEMPERATURE MICROORGANISMS
2y 5m to grant Granted Mar 17, 2026
Patent 12570939
EXTRACTION APPARATUS AND EXTRACTION METHOD FOR A FERMENTATION MEDIUM
2y 5m to grant Granted Mar 10, 2026
Patent 12564822
DEVICE FOR MANUFACTURE OF T-CELLS FOR AUTOLOGOUS CELL THERAPY
2y 5m to grant Granted Mar 03, 2026
Patent 12558650
IMPROVED DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
91%
With Interview (+30.0%)
3y 8m
Median Time to Grant
Low
PTA Risk
Based on 940 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month